Teknova Inc (TKNO): רווח למניה בשנים עשר החודשים האחרונים

Alpha Teknova, Inc. (TKNO) provides the biopharmaceutical sector with custom buffers and culture media. The TTM net income per share confirms the company's financial stability, with the current value standing at -0.30. Profit growth is supported by the expansion of production facilities for gene therapy. This technological leap is being finalized through the implementation of AI-driven automation systems for reagent dosing and packaging.

The efficiency of Alpha Teknova, Inc. (TKNO) scalable biopharmaceutical reagent production is reflected in the trailing twelve-month EPS trend. This metric is calculated by dividing total annual net income by the total number of shares, allowing investors to assess the real capital cushion and eliminate the impact of the share count when analyzing the business's fundamental value.